

PTO 892 DEA/FCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NOTICE OF REFERENCES CITED	SERIAL NUMBER 09/446,820	Art Unit 1648	Attachment to Paper Number
			13

APPLICANTS : Sodroski, J. G., <i>et al.</i>

U.S. PATENT DOCUMENTS


*	DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	

OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Freed, E. O., <i>et al.</i> , 1991, "Identification of the principle neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.", J. Virol. 65(1):190-194.
	McKeating, J. A., <i>et al.</i> , 1992, "Amino acid residues of the human immunodeficiency virus type 1 gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.", Virol. 190:134-142.
	Thali, M., <i>et al.</i> , 1993, "Characterization of conserved human immunodeficiency virus type 1 and gp120 neutralization epitopes exposed upon gp120-CD4 binding.", J. Virol. 67(7):3978-3988.
	Sullivan, N., <i>et al.</i> , 1993, "Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.", J. Virol. 67(6):3674-3679.
	Cao, J., <i>et al.</i> , 1993, "Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.", J. Virol. 67(5):2747-2755.

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE 07/10/03	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).) PAGE 1 OF 1
---	----------------------	---